Clinical trials
Prostate Cancer Screening clinical trials
Below are recruiting prostate cancer screening clinical trials, each written for real people, not researchers. We’re tracking 300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07230106RecruitingPhase 2
Study of 3 drugs for men with prostate cancer
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
Nanjing, JiangsuAges 18–80 - NCT07231159Recruiting
Cancer screening help at community spots
This trial tests a program to help people get screened for lung, breast, or prostate cancer at community resource spots. If you are at risk and screen positive, you may be able to join.
Orlando, FloridaAges 18 years+ - NCT05852041RecruitingEarly Phase 1
PET-MRI scan to find prostate cancer before active surveillance
This early-phase study tests a special PET-MRI scan using rhPSMA-73 to better detect prostate cancer areas in men who would otherwise choose active surveillance. It may help doctors see where (and how much) cancer is present before deciding on treatment.
Chicago, IllinoisAges 18 years+ - NCT07253987Recruiting
Cancer Survivors Program for Breast or Prostate Cancer
This study offers a program to help people who have completed their main treatment for early-stage breast or prostate cancer. It focuses on follow-up and support during survivorship, and you are still eligible if you are on certain maintenance therapies like hormone therapy.
BrnoAges 18 years+ - NCT07255664RecruitingPhase 1/Phase 2
TIL therapy for advanced colorectal or prostate cancer
This trial tests a new type of immunotherapy that uses your own white blood cells (TILs) to fight advanced colorectal or prostate cancer. You will have surgery to remove a tumor, then your TIL cells are grown in a lab and given back to you along with other treatments to boost your immune system.
FrankfurtAges 18 years+ - NCT07319923Recruiting
AI early warning system for prostate and bladder cancer in Beijing men
This trial is testing an AI-based early warning system to find prostate and bladder cancer earlier. It is for men over 50 living in Beijing who are willing to take part in the screening and follow-up process.
BeijingAges 18–85 - NCT07335796RecruitingPhase 2
Testing a new drug combination before prostate cancer surgery
This trial tests a new drug (BMS-986365) combined with another hormone therapy (degarelix) before radical prostatectomy for high-risk prostate cancer. The goal is to see if this combination helps lower cancer activity before surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT07339267RecruitingPhase 1
Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Beijing, Beijing MunicipalityAges 18–85 - NCT07363486RecruitingPhase 1/Phase 2
Study of 225Ac-LNC1011 for advanced prostate cancer
This trial tests a new radioactive drug called 225Ac-LNC1011 for men with a specific type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease.
Fuzhou, FujianAges 18–90 - NCT07393867RecruitingPhase 2
PSMA-guided radiation boost for prostate cancer
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
Boston, MassachusettsAges 18 years+ - NCT02543905Recruiting
Profile study for men at higher prostate cancer risk
This trial looks at how inherited risk (family history or gene findings) relates to screening and treatment for prostate cancer. If you qualify, you may be offered prostate screening tests and follow-up to see how well risk information predicts next steps.
Sutton, SurreyAges 40–69 - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Huntsville, AlabamaAges 18 years+ - NCT06826924Recruiting
Fasting or ketones for prostate cancer
This trial tests whether a 7-day water-only fast or taking ketone supplements can help treat prostate cancer. You would have a biopsy before and after to see how the tumor responds.
Baltimore, MarylandAges 18 years+ - NCT07590934RecruitingPhase 1/Phase 2
Testing new cancer drugs for advanced prostate cancer
This study tests new anti-cancer drugs for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to find treatments that work when standard drugs no longer help.
Encino, CaliforniaAges 18–99 - NCT07407283RecruitingPhase 1/Phase 2
Study of SHR-4394 combination therapy for prostate cancer
This trial tests a new drug called SHR-4394 combined with standard hormone therapy for men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination can help control the cancer.
Chengdu, SichuanAges 18–85 - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT07422597Recruiting
MRI or risk calculator for suspected prostate cancer
This trial compares using an upfront MRI versus a risk calculator to decide who needs a prostate biopsy. It may help men with suspected localized prostate cancer avoid unnecessary biopsies.
LevangerAges 50–75 - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07562438RecruitingPhase 2
Lutetium-177 Treatment for Advanced Prostate Cancer
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Fuzhou, FujianAges 18–90 - NCT07583160Enrolling by invitationPhase 1
YS247 Vaccine for Advanced Prostate Cancer
This trial tests a personalized cancer vaccine (YS247) designed to train your immune system to recognize and fight your prostate cancer. It may help slow or stop cancer growth in men whose cancer has spread and stopped responding to standard hormone treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06505356Enrolling by invitation
Genetics and inflammation in prostate cancer stage
This study looks at the connection between genetics, inflammation, and prostate cancer stage. It aims to find markers that may help predict how aggressive the cancer is. You may be eligible if you are newly suspected of having prostate cancer and have not yet started treatment.
KaunasAges 18–100 - NCT06424275Enrolling by invitation
Prostate cancer screening trial for European men ages 50-69
This trial aims to raise awareness and screen for prostate cancer in men aged 50 to 69 across the European Union. You may be able to join if you have never been diagnosed with prostate cancer and haven't had a prostate biopsy or MRI in the last six months.
DublinAges 50–69 - NCT06238661Enrolling by invitation
Prostate cancer screening pilot study for men 55-65
This study tests a new way to screen for prostate cancer in men aged 55 to 65 who live in a specific area of Italy. It aims to find cancer early when it's easier to treat.
Candiolo, ItalyAges 55–65 - NCT04254133Enrolling by invitation
Study uses genetics to guide prostate cancer care and screening
This study collects saliva and health/family history information to learn how inherited (genetic) factors relate to prostate cancer. The goal is to improve how treatment and future screening are planned for people and families.
Seattle, WashingtonAges 35–89
Hear when a new Prostate Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer screening?
- Yes. Clin2 currently lists 300 recruiting prostate cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.